PMID- 27158744
OWN - NLM
STAT- MEDLINE
DCOM- 20170207
LR  - 20220321
IS  - 1744-5116 (Electronic)
IS  - 1388-0209 (Linking)
VI  - 54
IP  - 11
DP  - 2016 Nov
TI  - Effect of mulberry leaf (Folium Mori) on insulin resistance via IRS-1/PI3K/Glut-4 
      signalling pathway in type 2 diabetes mellitus rats.
PG  - 2685-2691
AB  - CONTEXT: Folium Mori, the leaf of Morus alba L. (Moraceae), has been used in 
      traditional Chinese medicine (TCM) for treating diabetes. However, it is unclear 
      which components in the mulberry leaf are effective for the treatment of type 2 
      diabetes mellitus (T2DM). OBJECTIVE: To investigate the flavonoids and 
      polyphenols in mulberry leaves and their antihyperglycemic and antihyperlipidemic 
      effects in T2DM rats. MATERIALS AND METHODS: Male Sprague-Dawley rats were 
      divided into five groups: normal control (NC), diabetic control (DBC), diabetic 
      group with 0.3 mg/kg b.w./day rosiglitazone (RSG), diabetic group with 7 g/kg 
      b.w./day TCM formula and diabetic group with 2 g/kg b.w./day Folium Mori extract 
      (FME). After 4 weeks, the rats were sacrificed; biochemical parameters, gene and 
      protein expression were measured. RESULTS: The FBG level was significantly lower 
      in the FME group than in the DBC group (p < 0.05). In oral glucose tolerance 
      test, the AUC was significantly lower in the FME group (p < 0.05). The HOMA-IR 
      level was significantly decreased in the FME group (p < 0.05). FME decreased the 
      total cholesterol (TC), triglyceride (TG) and low density lipoprotein (LDL) 
      levels (p < 0.05). FME increased the mRNA and protein expression of IRS-1, PI3K 
      p85alpha and Glut-4 increased significantly (p < 0.05). Histological analysis 
      revealed amelioration of lipid accumulation following FME treatment. 
      Additionally, immunohistochemical analysis displayed stronger staining of Glut-4 
      in the FME group compared to the DBC group. DISCUSSION AND CONCLUSION: FME could 
      decrease the body weight, blood glucose, TG, TC and LDL levels, and improve 
      insulin resistance. FME possessed significant antihyperglycemic and 
      antihyperlipidemic activities via the IRS-1/PI3K/Glut-4 signalling pathway.
FAU - Cai, Shengyu
AU  - Cai S
AD  - a Beijing University of Chinese Medicine , Beijing , P.R. China.
FAU - Sun, Wen
AU  - Sun W
AD  - b Key Laboratory of the Health-Cultivation of the Ministry of Education , Beijing 
      University of Chinese Medicine , Beijing , P.R. China.
AD  - c Beijing Key Laboratory of the Health-Cultivation , Beijing , P.R. China.
AD  - d Beijing International Technology Cooperation Base for Prevention and Treatment 
      of Diabetes Mellitus with Chinese Medicine , Beijing , P.R. China.
FAU - Fan, Yixin
AU  - Fan Y
AD  - e Department of Science and Technology , Beijing University of Chinese Medicine , 
      Beijing , P.R. China.
FAU - Guo, Xuan
AU  - Guo X
AD  - f Dongfang Hospital Affiliated to Beijing University of Chinese Medicine , 
      Beijing , P.R. China.
FAU - Xu, Guangyuan
AU  - Xu G
AD  - f Dongfang Hospital Affiliated to Beijing University of Chinese Medicine , 
      Beijing , P.R. China.
FAU - Xu, Tunhai
AU  - Xu T
AD  - g School of Chinese Pharmacy , Beijing University of Chinese Medicine , Beijing , 
      P.R. China.
FAU - Hou, Yi
AU  - Hou Y
AD  - f Dongfang Hospital Affiliated to Beijing University of Chinese Medicine , 
      Beijing , P.R. China.
FAU - Zhao, Baosheng
AU  - Zhao B
AD  - h Scientific Research Experiment Center, Beijing University of Chinese Medicine , 
      Beijing , P.R. China.
FAU - Feng, Xingzhong
AU  - Feng X
AD  - i Beijing Shijitan Hospital, Capital Medical University , Beijing , P.R. China.
FAU - Liu, Tonghua
AU  - Liu T
AD  - b Key Laboratory of the Health-Cultivation of the Ministry of Education , Beijing 
      University of Chinese Medicine , Beijing , P.R. China.
AD  - c Beijing Key Laboratory of the Health-Cultivation , Beijing , P.R. China.
AD  - d Beijing International Technology Cooperation Base for Prevention and Treatment 
      of Diabetes Mellitus with Chinese Medicine , Beijing , P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20160509
PL  - England
TA  - Pharm Biol
JT  - Pharmaceutical biology
JID - 9812552
RN  - 0 (Glucose Transporter Type 4)
RN  - 0 (Insulin Receptor Substrate Proteins)
RN  - 0 (Irs1 protein, rat)
RN  - 0 (Plant Extracts)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - Glucose/metabolism
MH  - Glucose Transporter Type 4/*physiology
MH  - Insulin Receptor Substrate Proteins/*physiology
MH  - *Insulin Resistance
MH  - Lipid Metabolism/drug effects
MH  - Male
MH  - *Morus
MH  - Muscle, Skeletal/drug effects/metabolism
MH  - Phosphatidylinositol 3-Kinases/*physiology
MH  - Plant Extracts/*pharmacology
MH  - Plant Leaves
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Signal Transduction/*drug effects
OTO - NOTNLM
OT  - Antihyperglycemic effect
OT  - antihyperlipidemic effect
OT  - flavonoids
OT  - polyphenols
OT  - skeletal muscle
EDAT- 2016/05/10 06:00
MHDA- 2017/02/09 06:00
CRDT- 2016/05/10 06:00
PHST- 2016/05/10 06:00 [pubmed]
PHST- 2017/02/09 06:00 [medline]
PHST- 2016/05/10 06:00 [entrez]
AID - 10.1080/13880209.2016.1178779 [doi]
PST - ppublish
SO  - Pharm Biol. 2016 Nov;54(11):2685-2691. doi: 10.1080/13880209.2016.1178779. Epub 
      2016 May 9.